NCT04671407View on ClinicalTrials.gov

The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions
TCC
Interventions
DRUG

Hypertonic Saline

Hypertonic Saline 3% and 0.9%

Trial Locations (1)

Unknown

RECRUITING

Kaplan MC, Rehovot

Sponsors
All Listed Sponsors
lead

Kaplan Medical Center

OTHER

NCT04671407 - The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter